中药单体白花丹醌对鲍曼不动杆菌的耐药逆转作用

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (2): 155-159.

中药单体白花丹醌对鲍曼不动杆菌的耐药逆转作用

李娟¹, 李小宁², 钟正灵¹, 储冀汝¹, 余文涛¹, 张雪峰³, 谢海棠¹

¹皖南医学院第一附属医院弋矶山医院临床药学部;
²检验科,芜湖 241001,安徽;
³皖南医学院,芜湖 241000,安徽

收稿日期:2014-12-25 修回日期:2015-01-25 出版日期:2015-02-26 发布日期:2015-03-20
通讯作者: 谢海棠,女,博士,研究员、教授,硕士生导师,研究方向:遗传药代动力学。Tel: 0553-5738350 E-mail: xiehaitang@sina.com;李小宁,男,硕士,主任检验师,硕士生导师,研究方向:微生物检验。Tel: 0553-5739410 E-mail:lixiaoning19702006@126.com
作者简介:李娟, 女, 硕士研究生,助理研究员,研究方向:药物治疗学。Tel: 0553-5738350 E-mail: drugsina@163.com
基金资助:
安徽省高等学校省级自然科学研究项目(KJ2013B307);皖南医学院重点科研项目培育基金(WK2012ZF03)

Drug resistance reversing effect of Chinese herb monomer plumbagin on baumanii

LI Juan¹, LI Xiao-ning², ZHONG Zheng-ling¹, CHU Ji-ru¹, YU Wen-tao¹, ZHANG Xue-feng³, XIE Hai-tang¹

¹Department of Clinical Pharmacy;
²Department of Clinical Laboratory, First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu 241001, Anhui, China;
³Wannan Medical College, Wuhu 241000,Anhui,China

Received:2014-12-25 Revised:2015-01-25 Online:2015-02-26 Published:2015-03-20

摘要/Abstract

摘要： 目的: 探索中药单体白花丹醌对临床分离的鲍曼不动杆菌耐药性的逆转作用。方法: 取临床分离的鲍曼不动杆菌53株,检测其对临床常用的14种抗菌药物的敏感性。观察中药单体白花丹醌对标准菌株的直接作用。在确定白花丹醌以及羰基氰化氯苯腙(CCCP)的工作浓度以后,观察对比白花丹醌与阳性药CCCP的外排抑制试验结果。结果: 临床分离的53株鲍曼不动杆菌对临床常用的14种抗菌药物耐药率较高,其中氨苄西林、头孢唑啉、头孢呋辛、头孢西丁耐药率最高,分别为100%、100%、98.1%、98.1%。其余药物耐药率也均在50%以上。白花丹醌对标准质控菌的直接抗菌作用较弱。而白花丹醌与CCCP均显示了对庆大霉素、诺氟沙星、米诺环素和氯霉素的增敏作用,其外排阳性率分别达 11.3%和 18.9%,3.8%和 7.5%,13.2%和 17.0%,28.3%和 20.8%,两组之间无统计学差异(P>0.05)。结论: 鲍曼不动杆菌临床耐药情况严重,而白花丹醌作为一种中药单体可能具有一定的耐药逆转作用。

关键词: 白花丹醌, CCCP, 鲍曼不动杆菌, 耐药

Abstract: AIM: To explore the drug resistance reversing effect of Chinese herb simple substance plumbagin on baumanii. METHODS: Fifty-three strains of baumanii were isolated from patients. The antibacterial activities of 14 kinds of antibacterial drugs commonly used in clinic were detected. The direct antibacterial activities of Chinese herb monomer of plumbagin on standard strains were studied. After the determination of plumbagin and carbonyl cyanide m-chlorophenylhydrazone(CCCP) work concentration, the efflux inhibition test results of plumbagin and CCCP were compared.RESULTS: The resistance rate of 53 clinical isolates of baumanii to 14 kinds of clinical commonly used antimicrobial drugs was high.The ampicillin,cefazolin, cefuroxime, cefoxitin resistance rate was highest,respectively 100%,100%,98.1% and 98.1%. The rest of the drug-resistant rate is above 50%.The direct antimicrobial effect of plumbagin on quality standard bacteria was weak. Plumbagin and CCCP showed increasing sensitization to gentamicin, norfloxacin, minocycline hydrochloride and chloramphenicol. Their positive rates of efflux were 11.3% and 18.9%, 3.8% and 7.5%, 13.2% and 20.8%, 28.3% and 20.8%, respectively. There were no statistical differences between two groups.CONCLUSION: The clinical drug resistance of baumanii is in serious condition, and plumbagin as a kind of traditional Chinese medicine monomer may have a certain role in the drug resistance reversal.

Key words: plumbagin, CCCP, baumanii, drug resistance

中图分类号:

R965.2

李娟, 李小宁, 钟正灵, 储冀汝, 余文涛, 张雪峰, 谢海棠. 中药单体白花丹醌对鲍曼不动杆菌的耐药逆转作用[J]. 中国临床药理学与治疗学, 2015, 20(2): 155-159.

LI Juan, LI Xiao-ning, ZHONG Zheng-ling, CHU Ji-ru, YU Wen-tao, ZHANG Xue-feng, XIE Hai-tang. Drug resistance reversing effect of Chinese herb monomer plumbagin on baumanii[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 155-159.

参考文献

[1] Peleg AY,Seifert H,Paterson DL.Acinetobacter baumannii:emergence of asuccessful pathogen[J].Clin Microbiol Rev, 2008,21(3):538-582.
[2] Livermore DM.Has the eraofuntreatable infections arrived[J]?J Antimicrob Chemother,2009,64(Suppl1):i29-36.
[3] Tao C,Kang M,Chen Z,et al. Microbiologic study of the pathogens isolated from woundculture among Wenchuan earthquake survivors[J].Diagn Microbiol Infect DIS,2009,63(3):268-270.
[4] Pagès JM, Amaral L, Fanning S. An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat gram-negative resistant bacteria[J]. Curr Med Chem, 2011,18(19):2969-2980.
[5] Pagès JM, Amaral L. Mechanisms of drug efflux and strategies to combat them: Challenging the efflux pump of Gram-negative bacteria[J]. Biochim Biophys Acta, 2009, 1794(5):826-833.
[6] Pagès JM, Sandrine AF, Mahamoud A, et al.Efflux pumps of gram-negative bacteria, a new target for new molecules[J]. Curr Top Med Chem, 2010, 10(18):1848-1857.
[7] Padhye S, Dandawate P, Yusufi M, et al. Perspectives on medicinal properties of plumbagin and its analogs[J]. Med Res Rev, 2012, 32(6):1131-1158.
[8] Koh KH, Tham FY.Screening of traditional Chinese medicinal plants for quorum-sensing inhibitors activity[J]. J Microbiol Immunol Infect, 2011,44(2):144-148.
[9] Padhye S, Dandawate P, Yusufi M, et al. Perspectives on medicinal properties of plumbagin and its analogs[J]. Med Res Rev, 2012 ,32(6):1131-1158.
[10]周云.多种外排泵抑制剂逆转鲍曼不动杆菌耐药性的研究[D].川北医学院,2011.
[11]凌保东. 鲍曼不动杆菌抗生素多重耐药性:耐药机制与感染治疗对策[J].中国抗生素杂志, 2010,35(4) :241-254.
[12]李小宁,李娟,姚永红. 鲍曼不动杆菌的耐药性及产ESBL和碳青霉烯酶分析[J].中国临床药理学与治疗学,2012,17(1):30-33.
[13]Fernandez-Cuenca F,Martinez-Martinez L,Conejo MC,et a1.Relationship between β-lactamase production,outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii[J].J Antimicrob Chemother,2003,51(3):565-574.
[14]Jacoby GA.Mechanisms of resistance to quinolones[J].Clin Infect Dis,2005,41 (Suppl 2):S120-126.
[15]Yamane K,Wachino J,Doi Y,et al.Global spread of multiple aminoglycoside resistance genes[J].Emerg Infect Dis,2005,11(6):951-953.
[16]Nikaido H.Molecular basis of bacterial outer membrane permeability revisited[J].Microbiol Mol Biol Rev, 2003,67(4):593-656.
[17]McMurray LM, Petrucci RE, Levy SB. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli[J]. Proc Natl Acad Sci USA,1980,77(7):3974.
[18]Lin L,Ling BD,Li XZ.Distribution of the multidrug efflux pump genes,adeABC,adeDE and adelJK,and class 1 integron genes in multiple-anfimicrobial-resistant clinical isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex[J].Int J Antimicrob Agents,2009,33(1):27-32.
[19]何玉明.中药对细菌耐药性干预的研究进展[C]. 第二届临床中药学学术研讨会论文集,2009.
[20]霍仕霞,闫明. 白花丹的研究进展[J].中国医药导报,2008,5(28):17-18.